Precigen (PGEN) Competitors $1.45 +0.03 (+2.11%) Closing price 04:00 PM EasternExtended Trading$1.48 +0.03 (+1.72%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PGEN vs. CNTA, ARQT, TARS, BEAM, SPRY, ADPT, IMCR, SDGR, EWTX, and BHVNShould you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Centessa Pharmaceuticals (CNTA), Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), ARS Pharmaceuticals (SPRY), Adaptive Biotechnologies (ADPT), Immunocore (IMCR), Schrodinger (SDGR), Edgewise Therapeutics (EWTX), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Precigen vs. Its Competitors Centessa Pharmaceuticals Arcutis Biotherapeutics Tarsus Pharmaceuticals Beam Therapeutics ARS Pharmaceuticals Adaptive Biotechnologies Immunocore Schrodinger Edgewise Therapeutics Biohaven Centessa Pharmaceuticals (NASDAQ:CNTA) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations. Which has preferable valuation & earnings, CNTA or PGEN? Precigen has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M256.77-$235.76M-$1.81-7.28Precigen$3.92M109.19-$126.24M-$0.56-2.59 Do institutionals & insiders believe in CNTA or PGEN? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 7.1% of Centessa Pharmaceuticals shares are owned by insiders. Comparatively, 47.1% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is CNTA or PGEN more profitable? Centessa Pharmaceuticals has a net margin of 0.00% compared to Precigen's net margin of -3,728.87%. Centessa Pharmaceuticals' return on equity of -40.22% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -40.22% -29.95% Precigen -3,728.87%-279.20%-79.74% Do analysts prefer CNTA or PGEN? Centessa Pharmaceuticals presently has a consensus price target of $27.89, indicating a potential upside of 111.76%. Precigen has a consensus price target of $6.00, indicating a potential upside of 313.79%. Given Precigen's higher probable upside, analysts clearly believe Precigen is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Precigen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer CNTA or PGEN? In the previous week, Centessa Pharmaceuticals had 11 more articles in the media than Precigen. MarketBeat recorded 12 mentions for Centessa Pharmaceuticals and 1 mentions for Precigen. Precigen's average media sentiment score of 0.93 beat Centessa Pharmaceuticals' score of 0.46 indicating that Precigen is being referred to more favorably in the news media. Company Overall Sentiment Centessa Pharmaceuticals Neutral Precigen Positive Which has more volatility & risk, CNTA or PGEN? Centessa Pharmaceuticals has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. SummaryCentessa Pharmaceuticals beats Precigen on 8 of the 14 factors compared between the two stocks. Get Precigen News Delivered to You Automatically Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGEN vs. The Competition Export to ExcelMetricPrecigenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$419.16M$2.87B$5.52B$8.85BDividend YieldN/A2.70%5.36%4.13%P/E RatioN/A21.1726.3119.76Price / Sales109.19263.83409.02110.15Price / CashN/A41.2925.8827.49Price / Book11.157.237.915.36Net Income-$126.24M-$55.05M$3.15B$248.34M7 Day Performance-3.33%-0.74%0.95%1.25%1 Month Performance9.85%6.27%5.25%5.41%1 Year Performance-6.45%0.19%32.63%18.06% Precigen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGENPrecigen3.9943 of 5 stars$1.45+2.1%$6.00+313.8%-10.1%$419.16M$3.92M0.00190CNTACentessa Pharmaceuticals3.0997 of 5 stars$13.00+4.6%$27.89+114.5%+45.5%$1.74B$6.85M-7.18200ARQTArcutis Biotherapeutics2.1896 of 5 stars$14.40+4.2%$18.80+30.6%+50.8%$1.72B$196.54M-13.85150Positive NewsTARSTarsus Pharmaceuticals2.2744 of 5 stars$40.60-0.1%$66.67+64.2%+49.0%$1.71B$182.95M-14.8750Positive NewsBEAMBeam Therapeutics2.3453 of 5 stars$16.71-0.3%$48.75+191.7%-27.4%$1.68B$63.58M-3.62510SPRYARS Pharmaceuticals3.0867 of 5 stars$16.57+4.9%$31.00+87.1%+105.1%$1.63B$89.15M-103.5690Positive NewsAnalyst UpgradeInsider TradeADPTAdaptive Biotechnologies3.2951 of 5 stars$10.56+1.7%$10.57+0.1%+221.8%$1.60B$178.96M-11.00790Gap DownIMCRImmunocore2.4477 of 5 stars$31.12-0.7%$58.89+89.2%-7.4%$1.56B$310.20M-72.37320SDGRSchrodinger2.6082 of 5 stars$20.35-0.5%$32.80+61.2%+4.0%$1.49B$230.49M-7.74790EWTXEdgewise Therapeutics3.47 of 5 stars$14.18-0.8%$39.78+180.5%-27.2%$1.49BN/A-9.1560News CoverageAnalyst ForecastBHVNBiohaven2.7658 of 5 stars$14.44-0.2%$58.46+305.0%-59.3%$1.47BN/A-1.54239 Related Companies and Tools Related Companies CNTA Competitors ARQT Competitors TARS Competitors BEAM Competitors SPRY Competitors ADPT Competitors IMCR Competitors SDGR Competitors EWTX Competitors BHVN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGEN) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
